UI-014 is under clinical development by Korea United Pharm and currently in Phase I for Endocrine Gland Disorders. According to GlobalData, Phase I drugs for Endocrine Gland Disorders have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how UI-014’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UI-014 is under development for the treatment of endocrine, unspecified nutritional, metabolic diseases and hyperlipidaemia. It is administered through oral route. The drug candidate is an incrementally modified drug.
Korea United Pharm overview
Korea United Pharm (KUP) is a pharmaceutical company that produces, markets, sells and distributes pharmaceutical and other healthcare products. It offers incrementally modified drug, anti-cancer, prescription, OTC products, and others. The company provides anti-cancer products such as bleomycin sulfate, carboplatin, cyclophosphamide, dactinomycin and daunorubicin HCl, among others. KUP provides API products such as talniflumate, simvastatin, paroxetine and carvedilol. The company offers prescription product such as iohexol, arginine thiazolidine carboxylate, domperidone maleate, adefovir dipivoxil, entecavir, trimebutine maleate, and omeprazole enteric granule, among others. Its products are used in the therapeutic areas of gastrointestinal, cardiovascular, hematopoietic, respiratory, central nervous system, musculoskeletal, endocrine and metabolic, and other disorders. The company operates through its branch offices located in the Philippines, Vietnam, Myanmar, China, and others. KUP is headquartered in Seoul, South Korea.
For a complete picture of UI-014’s drug-specific PTSR and LoA scores, buy the report here.